News Brief: TrialNet Explores Plasmid Therapy for Type 1 Diabetes
Phase 1 study now recruiting adults diagnosed in past 4 years
JANUARY 14, 2021—TrialNet is testing a new plasmid therapy in adults diagnosed with type 1 diabetes in the past 4 years.
Designed by Novo Nordisk, NNC0361-0041 is a recombinant supercoiled plasmid encoding four human proteins: pre-proinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2). Preclinical findings show these therapies working together might retrain the immune system to stop attacking insulin-producing beta cells.
This is a Phase 1 study, meaning it is the first time this plasmid is being tested in people. If the study results in no safety concerns, TrialNet plans to conduct a larger study to see if the same treatment can slow or stop disease progression in high-risk individuals prior to type 1 diabetes diagnosis.
To learn more about this study, visit www.trialnet.org/topple
# # #
The largest clinical trial network ever assembled to change the course of type 1 diabetes, TrialNet offers free risk screening for relatives of people with type 1 diabetes and innovative clinical studies testing ways to maintain insulin production before and after diagnosis. TrialNet is funded by the National Institutes of Health (NIH), primarily through the Special Statutory Funding Program for Type 1 Diabetes. Visit trialnet.org
For additional information or to request an interview with TrialNet Chair Carla Greenbaum, M.D., please contact:
Annie Shultz, Program Manager, TrialNet Hub at the Benaroya Research Institute